Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Spondyloarthritis
•
Infectious Disease
•
Pulmonology
•
Critical Care
•
Pulmonary Infections
How would you treat a patient with psoriatic arthritis who developed disseminated histoplasmosis while on adalimumab and previously failed all non-biologic DMARDs?
Would you feel comfortable using a non-TNF biologic DMARD?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?